2019
DOI: 10.3390/vaccines7010025
|View full text |Cite
|
Sign up to set email alerts
|

Pneumococcal Vaccines: Challenges and Prospects

Abstract: Infections with the bacterium Streptococcus pneumoniae are one of the most common causes of morbidity and mortality in children less than five years of age worldwide, mostly in low- and middle-income countries (LMICs) [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 7 publications
1
2
0
Order By: Relevance
“…The fold change in IgG concentration from baseline to 6 months post vaccination to these clinically significant serotypes was higher following 13vPCV vaccination compared to 23vPPV, with a significant difference for serotype 6A (median, 3.09 compared to 1.3; p = 0.005; Figure 5 B). Both vaccines failed to induce protective responses to serotype 3, consistent with previous findings [ 59 ].…”
Section: Resultssupporting
confidence: 92%
“…The fold change in IgG concentration from baseline to 6 months post vaccination to these clinically significant serotypes was higher following 13vPCV vaccination compared to 23vPPV, with a significant difference for serotype 6A (median, 3.09 compared to 1.3; p = 0.005; Figure 5 B). Both vaccines failed to induce protective responses to serotype 3, consistent with previous findings [ 59 ].…”
Section: Resultssupporting
confidence: 92%
“…However, current vaccine provide protection against many, but not all, types of pneumococcal bacteria. The high number of serotypes and the emergence of non-vaccine serotypes pose challenges in achieving broad coverage [ 19 ].…”
Section: Introductionmentioning
confidence: 99%
“…While most of the disease caused by ALRI pathogens is not vaccine preventable, some pathogen specific vaccines are available, such as the pneumococcal conjugate vaccine (PCV) [ 8 ] and the inactivated influenza vaccine (IIV) [ 9 ]. However, current PCVs only cover up to 13 of the more than 100 S. pneumoniae serotypes [ 10 , 11 ] and the IIV is only moderately effective due to annual strain changes in the influenza A virus (IAV) and it is not commonly given to infants [ 12 ]. RSV [ 13 ] and SARS-CoV-2 [ 14 , 15 ] vaccines are currently under development and may be available in the future.…”
Section: Introductionmentioning
confidence: 99%